Resource impact statement
No significant resource impact is anticipated
NICE has recommended palbociclib with fulvestrant as an option for treating hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer in adults who have had endocrine therapy only if:
- exemestane plus everolimus is the most appropriate alternative to a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor and
- the company provides palbociclib according to the commercial arrangement (see section 2 of the guidance).
We do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year (or approximately £9,000 per 100,000 population, based on a population for England of 56.3 million people).
This is because the technology is a further treatment option and a cost comparison suggests that palbociclib and the other treatment options (ribociclib and abemaciclib) have similar costs.
Palbociclib and the other treatment options (ribociclib and abemaciclib) have discounts that are commercial in confidence. It is the responsibility of the manufacturers to advise NHS organisations of the discounted prices.
This technology is commissioned by NHS England. Providers are NHS hospital trusts.
This page was last updated: